Characterizing genes associated with leukemic cells differentiation may provide help for understanding mechanisms on the leukemia differentiation. The aim of this study is to investigate whether the expression of melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) could be induced during leukemia differentiation, and whether mda-7/IL-24 plays a role in leukemia differentiation. We showed that the expression of mda-7/IL-24 and IL-24 delE5, a mda-7/IL-24 splice variant, was induced in 
Introduction
Acute myeloid leukemia (AML) is characterized by a block in myeloid differentiation.
Currently, most tumor treatment strategies are mainly focused on killing cancerous cells using chemotherapy, which has a number of toxic side effects and other important disadvantages. An alternate approach for treating cancer employs agents that modify tumor growth by inducing terminal differentiation, a process termed "differentiation therapy ". Since the establishment of all-trans retinoic acid (ATRA) as a differentiation therapy to treat acute promyelocytic leukemia (APL), APL has become a curable subtype of acute myelocytic leukemia (1) . Extensive efforts are being directed towards characterizing genes associated with leukemic cells differentiation. Achieving this goal may provide help for understanding mechanisms on the AML cells differentiation and designing safe and specific differentiation therapy to treat leukemia.
Melanoma differentiation-associated gene-7 (mda-7) was first identified as a gene whose expression correlates with the induction of terminal differentiation in human melanoma cells. Based on its chromosomal location, sequence homology, structure, and cytokine-like properties, mda-7 has also been named interleukin-24 (IL-24) (2) . Two splice variants of mda-7/IL-24 have been reported. One lacks exon 5 (IL-24 delE5), and the other lacks both exon 3 and exon 5 (mda-7s) (3) . mda-7s has minimal sequence homology to mda-7/IL-24 but functionally interacts with and inhibits the secretion of the wild-type protein (4) . In contrast, the IL-24 delE5 splice variant has high homology to mda-7/IL-24, but lacks the IL-10 signature motif and is weakly amplified in melanocytes Many studies have focused on the apoptosis inducing effect of mda-7/IL-24 on a broad spectrum of human cancers (2, 5) . The protein product of mda-7/IL-24 can exert its antitumor effect by binding to its two receptor complexes, IL-20R1/IL-20R2 or IL-22R1/IL-20R2 (6, 7) . Interestingly, when introduced into tumor cells by adenovirus transduction (Ad. mda-7), mda-7/IL-24 has a potent intracellular mode of action and is active through a receptor-independent mechanism (2, 6, 8) . Although mda-7/IL-24 expression correlates with induction of terminal differentiation in human melanoma cells, ectopic overexpression of mda-7/IL-24 causes growth suppression and apoptosis but no induction of differentiation in melanoma cells (9) .
12-O-tetradecanoylphorbol-13-acetate (TPA) is a well-known agent that signals differentiation of myeloid precursors and myeloid leukemia cell lines (10, 11) . It has been reported that TPA could increase the mda-7/IL-24 promoter activity in melanoma cells and HeLa cells (12, 13) . These data brings up an interesting possibility that mda-7/IL-24 can be induced during TPA-mediated leukemia differentiation. Herein we find the expression of mda-7/IL-24 is induced when TPA induces U937 and HL60 cells to undergo monocytic differentiation. Intriguingly, the expression of IL-24 delE5, a mda-7/IL-24 splice variant, is also induced during this process. Furthermore, we demonstrate that mda-7/IL-24 and IL-24 delE5 play an important role in the monocytic differentiation in leukemia cells mediated by TPA, and ectopic expression of mda-7/IL-24 and IL-24 delE5 induced myeloid leukemic cells to differentiate, without affecting normal hematopoietic 
Materials and Methods

Cell lines and reagents
HL60 (promyelocytic leukemia) and U937 (promonocytic leukemia) used in the research were obtained directly from American Type Culture Collection (ATCC) and were cultured as described (14) . These cell lines were passaged in our laboratory for fewer than 6 months after receipt. ATCC characterized these cell lines by DNA profiling.
TPA (Sigma, St Louis, MO, USA) was added to cells at a final concentration of 20 nM for U937 and HL60 cells. The mitogen activated protein kinase kinase (MEK) inhibitors U0126 and PD98059, and JNK inhibitor SP600125 were purchased from Calbiochem (San Diego, CA, USA). N-acetylcysteine (NAC) and diphenyleneiodonium (DPI) were purchased from Sigma.
RT-PCR
cDNA was synthesized by reverse transcribed of 2 ȝg RNA using a commercial kit (Promega Corporation, Madison, WI, USA). The following primers was used to amplify cDNA (2 ȝl) (forward/reverse): mda-7/IL-24 and IL-24 delE5: 5ƍ-ATGAATTTTCA ACAGAGGC-3ƍ/5ƍ-TCAGAGCTTGTAGAATTT-3ƍ; GAPDH: 5ƍ-TGAAGGTCGGAGTCAAC GGATTTGG-3ƍ/5ƍ-CATGTGGGCCATGAGGTCCACCAC-3ƍ. The products were sequenced using an ABI PRISM 3770 apparatus (Perkin Elmer Corp., Foster City, CA, USA). IL-24 delE5: 5'-CATTTTCTTGGCTCTCAGCATC-3'/5'-TGGGCTGTGAAAGACACTA-3'.
The comparative threshold cycle method was used for calculation of fold-amplification.
The expression level of each gene was normalized to the expression level of GAPDH.
RNA interference
mda-7/IL-24 siRNA (100 nM; Dharmacon, Chicago, IL., USA. Cat # LQ-007977-00) and non-targeting siRNA were transfected into cells using nucleofection (Amaxa, GmbH, Köln, Germany).
Plasmid Construction and transfection
The cDNAs for mda-7/IL-24 or IL-24 delE5 were cloned into the plasmid pIRES (BD Bioscience Clontech, Palo Alto, CA, USA) using the same primers (forward/reverse):
5ƍ-ATTGGATCCGGAACACGAGACTGAGAGATG-3ƍ/5ƍ-ATGTCGACAGGGAACAAACCA GTGCCA-3ƍ, and termed IRES-mda-7/IL-24 and IRES-IL-24 delE5, respectively. The resulting constructs were purified with a QIAGEN EndoFree Plasmid kit (QIAGEN, Hilden, See Supplementary Materials and Methods for details.
FACS assay for in vitro differentiation
The expression of differentiation-specific cell surface antigens was measured using scored. Colonies were confirmed by cytologic analysis after removal from the dish by micropipette and staining with Wright-Giemsa staining.
Ethical clearance was obtained from the Institute Ethics Committee and all participants gave informed consent.
FACS assay for ROS production
Cells were incubated with 10 ȝM 2ƍ, 7ƍ-dichlorodihydrofluorescein diacetate (H2DCF-DA) (Beyotime Institute of Biotechnology, Haimen, China) in PBS for 20 min at 37°C in the dark. The fluorescence intensity was monitored with an excitation wavelength of 488 nm and an emission wavelength of 530 nm.
Measurement of NADPH oxidase activity
NADPH oxidase activity was analyzed as described (15) . For analysis of specific oxidase activity, the rate of consumption of NADPH inhibited by DPI was measured, by adding 10 ȝM DPI (sigma) 30 min before the assays. All measurements were expressed in nanomoles of substrate/min/10 6 cells. Control cultures were treated with the solvent DMSO.
Statistical analysis
Statistical analysis was done with ANOVA, t-test, and Ȥ 2 using the SPSS software package (SPSS, Chicago, IL, USA). Differences were considered to be statistically 
Results
TPA induces the expression of mda-7/IL-24 and IL-24 delE5 in U937 and HL60 cell lines
We evaluated whether mda-7/IL-24 expression could be induced by TPA in U937 and HL60 cells. The expression of mda-7/IL-24 mRNA was first detected using RT-PCR with primers designed to amplify the full-length mda-7/IL-24 open reading frame, which facilitated detection of variant transcripts. We observed that mda-7/IL-24 mRNA expression could not be detected in the untreated cell lines, but was induced at 48 hours after TPA treatment (Fig. 1A) . Interestingly, in addition to the full-length mda-7/IL-24 transcript, an additional smaller transcript was also detected in U937 and HL60 cells during TPA-induced monocytic differentiation. Isolation, cloning, and sequencing of this transcript showed that the smaller species was a mda-7/IL-24 splice variant IL-24 delE5, which lacks exon 5 of the full-length mda-7/IL-24.
We then used real-time PCR to quantitate the expression of mda-7/IL-24 and IL-24 delE5, and found that the induction of both mda-7/IL-24 and IL-24 delE5 began to increase at 24 hours after TPA treatment ( Supplementary Fig. S1A ). Dose-response study showed that mda-7/IL-24 and IL-24 delE5 was induced dose dependently when U937 and HL60 cells were treated with TPA at concentrations less than 20 nM (data not shown). The relative expression levels of IL-24 delE5 and mda-7/IL-24 were also tested using quantitative real-time RT-PCR. The results showed that IL-24 delE5 mRNA levels were 20% of the levels of mda-7/IL-24 mRNA in U937 cells, and 30% of the levels of mda-7/IL-24 mRNA in HL60 cells (Fig. 1B) . The specificity of the mda-7/IL-24 and IL-24 delE5 primer sets was confirmed by sequencing PCR products and melting curve analysis. The mda-7/IL-24 and IL-24 delE5 proteins were analyzed by western blotting with a mda-7/IL-24-specific antibody recognizing regions common to both mda-7/IL-24 and IL-24 delE5. The two proteins were approximately 35 kDa and 24 kDa, which are consistent with the predicted molecular weights of mda-7/IL-24 and IL-24 delE5, respectively (Fig. 1C) .
The monocytic differentiation of U937 and HL60 cells induced by TPA were monitored by detecting the differentiation-specific cell surface antigens CD11b, CD14 and CD115 using FACS assay. We found that these markers began to increase at 24 hours after TPA treatment and reached a maximal level at 72 hours ( Supplementary Fig. S1B ). 
antibody against total ERK1/2 demonstrated no significant change in total ERK1/2 expression, indicating that treatment with TPA induces the activation of pre-existing ERK1/2.
Then, two MEK inhibitors, U0126 and PD98059, were used to demonstrate whether the phosphorylation of ERK1/2 is a phenomenon that regulates the expression of mda-7/IL-24 and IL-24 delE5 and the differentiation induced by TPA. As shown in Fig. 3B , the expression of mda-7/IL-24 and IL-24 delE5 induced by TPA was significantly attenuated by the two inhibitors. Moreover, as shown in Fig. 3C and D, adherence and differentiation of TPA-treated U937 and HL60 cells were almost completely inhibited by pretreatment with U0126 (10 ȝM) and partially inhibited by PD98059 (25 ȝM) (P < 0.001), whereas cell viability and proliferation were not significantly affected by the two inhibitors (data not shown).
We also evaluated the roles of the other two kinds of MAPK, c-Jun N-terminal kinases (JNK) and p38 mitogen-activated protein kinases (p38 MAPK), and showed that TPA treatment could not activate p38 MAPK, and although TPA significantly increased the phosphorylation level of JNK, the JNK inhibitor SP600125 did not inhibit induction of mda-7/IL-24 and IL-24 delE5 ( Supplementary Fig. S3A and B) .
These results strongly suggest that TPA induces mda-7/IL-24 and IL-24 delE5 expression by activating the MAPK/ERK pathway during U937 and HL60 cell monocytic differentiation. 
Ectopic overexpression of mda-7/IL-24 and IL-24 delE5 induces differentiation of acute myeloid leukemic cells
Our previous study showed that none of the hematopoietic malignant cell lines tested, including U937 and HL60, expressed mda-7/IL-24 intact receptor pairs, and recombinant mda-7/IL-24 had no effect on these cell lines (14) . To evaluate functional consequences of mda-7/IL-24 and IL-24 delE5 induction by TPA, mda-7/IL-24 and IL-24 delE5 were transiently transfected into U937 and HL60 cells respectively. Prior to the start of our study, a serial amount of these plasmids were transiently transfected into U937 and HL60 cells, and a dose-dependent increase in transfection and gene expression using less than 1 ȝg of plasmid was observed. Thus, 1 ȝg plasmid was used in all subsequent transfection experiments.
A transfection efficiency of 70% and 65% for U937 and HL60 cells, respectively, was typically observed using fluorescence microscopy. For each cell line, cells transfected with mda-7/IL-24 or IL-24 delE5 contained comparable expression of mda-7/IL-24 and IL-24 delE5 protein (Fig. 4A ). Transient transfection with mda-7/IL-24 or IL-24 delE5 in U937 and HL60 cells resulted in remarkably upregulated expression of the mature myeloid cell surface proteins CD11b and CD14 (p < 0.05), as compared with controls (Fig. 4B) . The expression of monocyte/macrophage surface marker CD115 was also increased in U937 cells, but not in HL60 cells (Fig. 4B) . In addition, a significant inhibition in cell growth, both in vitro and in vivo (p < 0.001; Supplementary Fig. S4A and B) , and a significant decrease in the number and size of colonies (p < 0.001; Supplementary Fig. S4C) but no significant induction of apoptosis was detected (p > 0.05; Supplementary Fig. S5 ).
These data suggest that ectopic overexpression of mda-7/IL-24 and IL-24 delE5 significantly induces differentiation and inhibits growth of U937 and HL60 cells.
To further investigate whether induction of differentiation also occurs in primary leukemic cells, we next tested 3 patient samples with acute monocytic leukemia. BMMCs were obtained, and transiently transfected with mda-7/IL-24 or IL-24 delE5. In all of the leukemia cells tested in the present study, ectopic overexpression of mda-7/IL-24 or IL-24 delE5 induce morphological evidence of differentiation, including nuclear condensation and shifting of the nuclear/cytoplasmic ratio from >1 to <1 (Fig. 4C) . The expression of CD11b, CD14 and CD115 was also enhanced to varying degrees (p < 0.05; Fig. 4D ). These results suggested mda-7/IL-24 and IL-24 delE5 were able to induce differentiation of blasts from patients with AML. However, as in the U937 and HL60 cell lines, no significant induction of apoptosis was observed (data not shown).
mda-7/IL-24 and IL-24 delE5 have no effect on normal hematopoietic progenitors
TPA has been shown to inhibit the colony formation of both leukemic progenitor cells (L-CFU) and normal myeloid colony (CFU-C) (17) . In our study, mda-7/IL-24 and IL-24 delE5 were shown to induce differentiation of leukemic cells. Thus, we next asked whether these genes affected normal hematopoietic progenitor cells. To address this issue, CD34 and the liquid culture assay showed that no significant difference in colony number, morphology, or the expression level of monocytic surface markers was observed as compared with control (p > 0.05; Fig. 5A and B) , suggesting that mda-7/IL-24 and IL-24 delE5 have no cytopathic and differentiation-inducing effect on normal hematopoietic precursors. Notably, no colonies or clusters were found when CD34 + cells were treated with TPA at concentrations of 100 nM, 50 nM, 25 nM, 10 nM, 5 nM, 2 nM, or 1 nM (data not shown).
mda-7/IL-24 and IL-24 delE5 induce differentiation of leukemic cells by promoting ROS production
Reactive oxygen species (ROS) regulate apoptosis and proliferation in response to a variety of stimuli (18) , and it also play important roles in cell differentiation and senescence (19) . An intriguing question is whether ROS can also mediate the differentiation of leukemic cells induced by mda-7/IL-24 and IL-24 delE5. To test this hypothesis, U937, HL60 cells and blasts from patients with AML-M5 transiently transfected with mda-7/IL-24 or IL-24 delE5 were stained for ROS production using H2DCF-DA. We observed mda-7/IL-24 or IL-24 delE5 increased the level of ROS in a time-dependent manner at 12 hours, 24 hours and 48 hours after transfection (data not shown), and the most prominent increase of ROS was at 48 hours (p < 0.05; Fig. 6A ).
To further study whether ROS is necessary for mda-7/IL-24-and IL-24 delE5-mediated differentiation, U937 and HL60 cells were treated with 25 ȝM of NAC after transfection. The predominant intracellular source of ROS generation in monocytes is NADPH oxidase (20, 21) . To analyze the source of ROS in the leukemic cells transfected with mda-7/IL-24 or IL-24 delE5, the effect of DPI, a well-known inhibitor of NADPH oxidase, on ROS production was examined. As shown in the Fig. 6C , the increase of ROS induced by mda-7/IL-24 and IL-24 delE5 was abrogated by 10 ȝM DPI. In addition, enzymatic activity assay showed that mda-7/IL-24 or IL-24 delE5 significantly increased NADPH oxidase activity in U937 and HL60 cells (Fig. 6D) . These results indicate that ROS induced by mda-7/IL-24 and IL-24 delE5 is mainly generated by NADPH oxidase. 
delE5 remains to be determined. Such analysis is currently hampered by the lack of an experimental strategy to individually silence each of the two mRNAs, because the two transcripts exhibit high homology.
To evaluate functional consequences of mda-7/IL-24 and IL-24 delE5, we examined the effect of mda-7/IL-24 and IL-24 delE5 on leukemic cells differentiation and proliferation. Our results suggested that ectoptic overexpression of mda-7/IL-24 or IL-24 delE5 significantly induced differentiation of the myeloid leukemia cell lines and blast cells without causing significant apoptosis, but we cannot rule out that mda-7/IL-24 or IL-24 delE5 have other effects such as autophagy. The expression of monocyte/macrophage surface marker CD115 was increased in U937 cells, but not in HL60 cells. It may be presumed that the cell lineage commitment and differentiation is dependent on the developmental level of the cell, rather than the types of differentiation regulator. mda-7/IL-24 has been described to induce apoptosis of B-lymphoblastic leukemia (25).
Our results show that mda-7/IL-24 inhibits AML growth and induce AML differentiation.
However, Sainz Perez et al report that high mda-7/IL-24 expression promotes malignant cell survival in CLL (23). One possible explanation for the diversity is that the effect of mda-7/IL-24 on leukemia is dependent on leukemia subtype.
Ectoptic overexpression of mda-7/IL-24 or IL-24 delE5 significantly inhibited the growth of U937 and HL60 cells both in vitro and in vivo. We found no statistically significant difference in all the antileukemia characteristics between mda-7/IL-24 and IL-24 delE5 time, we show that IL-24 delE5 exerts antileukemia effect in AML cells. Because the expression of IL-24 delE5 was always accompanied by full-length mda-7/IL-24 expression in U937 and HL60 cells treated with TPA, to rule out the possibility that functional activity requires coexistence of the two proteins, we also constructed a plasmid carrying both mda-7/IL-24 and IL-24 delE5 genes. We observed that the antitumor activity induced by the construct coexpressing mda-7/IL-24 and IL-24 delE5 was higher than that induced by mda-7/IL-24 or IL-24 delE5, but no synergistic effect could be found (data not shown).
TPA is an extraordinarily potent stimulator of differentiation of cultured human promyelocytic leukemia cells (26, 27) . However, clinical use of TPA has been hampered by the fact that, as a multifunctional substance, TPA is also a tumor promoter and proinflammatory agent, and it can cause serious adverse events in patients (28) . In our combination of superoxide ions and platelet-activating factor in rat monocytic leukemia c-WRT-LR cells (32) . These findings led us to speculate that ectopic overexpression of mda-7/IL-24 and IL-24 delE5 induces ROS production in leukemic cells. In agreement with this hypothesis, our results showed that transfection of mda-7/IL-24 or IL-24 delE5 in U937 and HL60 cells and blast cells increased ROS levels, and ROS was found to be required for cell differentiation. Furthermore, we observed that the increased ROS was mainly generated by NADPH oxidase. It has been reported that blasts isolated from patients with various types of leukemia showed a significant increase of the oxygen radicals in the malignant cells compared to normal leukocytes, and leukemic cells is intrinsically under oxidative stress and therefore more vulnerable to further stress (33, 34) . 
